Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Kit

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance

Wettan has served at Gilead for over 14 years

- PMLiVE

Gilead agrees on affordable medicines plan with US government

The company recently announced a $32bn investment in US R&D and manufacturing

- PMLiVE

Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

This is the most common type of non-Hodgkin lymphoma worldwide

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

The rare liver disease affects approximately 15 per 100,000 people in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links